Skip to main content

Dravet Syndrome (DS) clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

    Sorry, not currently recruiting here

    The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with Dravet Syndrome. Participants will receive their standard anti-seizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo looks just like soticlestat but will not have any medicine in it. Participants may continue treatment in an extension study, based on the extension study's entry criteria. Those that want to stop treatment will have a gradual dose reduction during 1 week and then be followed up for 2 weeks.

    San Francisco, California and other locations

Last updated: